Targeting HRD in Ovarian Cancer with PARP Inhibitors: Oral Olaparib Is Well Tolerated in Combination With Carboplatin in BRCA-Deficient Disease

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Targeting HRD in Ovarian Cancer with PARP Inhibitors: Oral Olaparib Is Well Tolerated in Combination With Carboplatin in BRCA-Deficient Disease

By Christina M. Annunziata 3 Videos

0 views

January 17, 2020

Credit: Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute.
This lecture was presented ...
read more ↘ in the series entitled "Translational Research in Clinical Oncology".
↖ read less

Comments 0

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Best Practices for the management of ocular adverse events associate…

Feat. K. Lamoreau

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton